PFS Partners’s Edwards Lifesciences EW Stock Holding History

PFS Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-60	Closed	-$5.73K	–	450
2024 Q1	$5.73K	Hold	60	–	–	﹤0.01%	331
2023 Q4	$4.58K	Hold	60	–	–	﹤0.01%	356
2023 Q3	$4.16K	Hold	60	–	–	﹤0.01%	356
2023 Q2	$5.66K	Buy	+60	New	+$5.21K	﹤0.01%	332

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

PFS Partners's EW Position: Q2 2024 in Review

PFS Partners sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 60 shares — an estimated $5.73K sold.

PFS Partners first reported a position in EW in Q2 2023 and held it in 4 quarters. The position peaked at $5.73K in Q1 2024. 1,297 funds tracked by Wall St. Rank hold EW as of Q2 2024.

PFS Partners reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
PFS Partners sold 60 Edwards Lifesciences shares in Q2 2024, an estimated $5.73K.
PFS Partners first reported a position in Edwards Lifesciences in Q2 2023 and held it in 4 quarters.
PFS Partners's Edwards Lifesciences position peaked at $5.73K in Q1 2024.
1,297 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.

Based on PFS Partners's 13F filing for Q2 2024, filed 25 Jul 2024.